Berkeley Lights Announces GSK Acquires Third Beacon® Optofluidic System to Expand Antibody Therapeutics Development
October 26 2021 - 8:32AM
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital
cell biology, today
announced that GlaxoSmithKline (NYSE: GSK) has
purchased an additional Beacon™ Optofluidic system to
expand its antibody therapeutics capacity. The new Beacon system
will leverage Berkeley Lights’ Opto™ Plasma B Discovery workflow to
perform functional analysis, further accelerating the lead
selection process.
"We are pleased that GSK has again selected the Beacon
Optofluidic system as part of their ongoing activities to
accelerate discovery, development, and delivery of
therapeutics," said Eric Hobbs, Ph.D., chief executive officer
of Berkeley Lights. “BLI’s platform represents a step change
in high-throughput screening technology and can be used to discover
new insights in functional biology research and therapeutics
discovery. GSK’s broadening adoption demonstrates the value of our
streamlined functional screening platform that is capable of
observing rare interactions, underpinned by a unique combination of
high-throughput screening and live biology.”
The Beacon system purchased by GSK is inclusive of the 13
new platform placements for the quarter ended September 30,
2021, which was pre-announced on October 12, 2021.
More on the Beacon systemThe Beacon system is
the most flexible, advanced high throughput functional screening
platform on the market with customers featuring the technology as
their competitive advantage in a variety of markets including
antibody discovery and cell line development, gene therapy and
synthetic biology.
The Beacon system workflow is proven to be a
better, more advanced way to process and analyze cells that
saves customers time, money, and effort because of its:
- Single cell-based workflow that shortens the selection process
to just days;
- Tracking of phenotype and genotype of single cells
or clones;
- Automation and scaling workflows far beyond manual,
time-intensive analysis; and
- Generation of greater insights through deep profiling of each
cell or clone.
Berkeley Lights Berkeley Lights is a
leading digital cell biology company focused on enabling and
accelerating the rapid development and commercialization of
biotherapeutics and other cell-based products for our customers.
The Berkeley Lights Platform captures deep
phenotypic, functional and genotypic information for
thousands of single cells in parallel and can also deliver the live
biology customers desire in the form of the best cells. Our
platform is a fully integrated, end-to-end solution, comprising
proprietary consumables, including our OptoSelect™ chips and
reagent kits, advanced automation systems, and application
software. We developed the Berkeley Lights Platform to provide the
most advanced environment for rapid functional characterization of
single cells at scale, the goal of which is to establish an
industry standard for our customers throughout their cell-based
product value chain.
Berkeley Lights’ Beacon® and Lightning™ systems and
Culture Station™ instrument are FOR RESEARCH USE
ONLY. Not for use in diagnostic procedures.
Forward-Looking Statements To the extent
that statements contained in this press release are not
descriptions of historical facts regarding Berkeley Lights or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company’s growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
Media ContactsMedia@berkeleylights.com
Investor Contact IR@berkeleylights.com
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024